Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
April 19 2022 - 7:10AM
Business Wire
– Company seeks proposals to create and
sustain community-focused programs to support underserved
populations with these conditions –
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today, affirmed its commitment to individuals living with
the systemic lupus erythematosus (SLE) and lupus nephritis (LN)
through the sponsorship of charitable grants to establish or expand
community-focused patient navigator programs. This is the second
year of this unique program aimed at eliminating barriers to care
for individuals living with SLE/LN. LN is a serious manifestation
of SLE that can cause irreversible kidney damage and kidney failure
and significantly affects more Black, Asian, and Hispanic
individuals than non-Hispanic White individuals. Selected
applicants may receive up to $50,000 over a one-year period.
The Request for Proposal (“RFP”) invites U.S. based charitable
organizations to submit proposals that outline the development and
execution of patient navigation programs that address barriers to
screening, treatment, and supportive care for individuals living
with SLE and LN. Grants will be awarded based on grantee ability to
collaborate with local lupus centers (community or academic) and
ability to deliver outcomes that:
- Educate patients on the importance of routine screenings and
medical appointments
- Enhance patient/provider communication
- Ensure patient’s basic needs are met (address social
determinants of health)
- Empower patients to make informed decisions about their
health
- Bridge access gaps
- Connect patients with resources needed to receive ongoing
treatment and medical care
Preference will be given to programs that support underserved
communities, specifically, Blacks, Hispanics, and Asians.
In the first year of the grants program, Aurinia awarded
$250,000 in Grants to support 5 patient navigation programs for a
12-month period (2021-2022). Throughout this time, grant recipients
convened regularly to share lessons learned, best practices, as
well as program metrics.
“The results from the first year of patient navigation grants
illustrate the measurable impact these programs can have on
improving diagnosis and disease management and supporting better
adherence to medical appointments and treatments,” said Jessica
Bateman, Advocacy Relations, Aurinia Pharmaceuticals. “We remain
committed to this important program and to doing our part to
mitigate the barriers to health equity and ultimately improve
outcomes for those living with SLE and LN.”
Organizations are encouraged to submit applications by June 10,
2022. The full RFP can be found here.
About Lupus Nephritis
Lupus nephritis (LN) is a serious manifestation of systemic
lupus erythematosus (SLE), a chronic and complex autoimmune
disease. About 200,000-300,000 people live with SLE in the U.S. and
approximately one out of three of these individuals develop LN. If
poorly controlled, LN can lead to permanent and irreversible tissue
damage within the kidney, resulting in kidney failure. Black and
Asian individuals with SLE are four times more likely to develop LN
and individuals of Hispanic ancestry are approximately twice as
likely to develop the disease when compared with Caucasian
individuals. Black and Hispanic individuals with SLE also tend to
develop LN earlier and have poorer outcomes when compared to
Caucasian individuals.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by serious diseases with a high unmet
medical need. In January 2021, the Company introduced LUPKYNIS™
(voclosporin), the first FDA-approved oral therapy for the
treatment of adult patients with active LN. The Company’s head
office is in Victoria, British Columbia, its U.S. commercial hub is
in Rockville, Maryland, and the Company focuses its development
efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220419005452/en/
Corporate/Media: Dana Lynch Corporate Communications,
Aurinia dlynch@auriniapharma.com
Investors: Investor Relations & Corporate
Communications, Aurinia aurinia@westwicke.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024